Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Remington GM, Treadaway K, Frohman T, Salter A, Stüve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, Frohman EM. Remington GM, et al. Among authors: treadaway k. Ther Adv Neurol Disord. 2010 Jan;3(1):3-13. doi: 10.1177/1756285609355851. Ther Adv Neurol Disord. 2010. PMID: 21180632 Free PMC article.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stüve O, Greenberg BM, Racke MK, Zivadinov R. Frohman EM, et al. Among authors: treadaway k. Ther Adv Neurol Disord. 2010 Jan;3(1):15-28. doi: 10.1177/1756285609353354. Ther Adv Neurol Disord. 2010. PMID: 21180633 Free PMC article.
Symptomatic therapy in multiple sclerosis.
Frohman TC, Castro W, Shah A, Courtney A, Ortstadt J, Davis SL, Logan D, Abraham T, Abraham J, Remington G, Treadaway K, Graves D, Hart J, Stuve O, Lemack G, Greenberg B, Frohman EM. Frohman TC, et al. Among authors: treadaway k. Ther Adv Neurol Disord. 2011 Mar;4(2):83-98. doi: 10.1177/1756285611400658. Ther Adv Neurol Disord. 2011. PMID: 21694806 Free PMC article.
Multiple sclerosis.
Courtney AM, Treadaway K, Remington G, Frohman E. Courtney AM, et al. Among authors: treadaway k. Med Clin North Am. 2009 Mar;93(2):451-76, ix-x. doi: 10.1016/j.mcna.2008.09.014. Med Clin North Am. 2009. PMID: 19272518 Review.
Factors that influence adherence with disease-modifying therapy in MS.
Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stüve O, Racke M, Frohman EM. Treadaway K, et al. J Neurol. 2009 Apr;256(4):568-76. doi: 10.1007/s00415-009-0096-y. Epub 2009 Apr 27. J Neurol. 2009. PMID: 19444532
Neurotherapeutic Strategies for Multiple Sclerosis.
Frohman TC, Beh SC, Kildebeck EJ, Narayan R, Treadaway K, Frohman EM. Frohman TC, et al. Among authors: treadaway k. Neurol Clin. 2016 Aug;34(3):483-523. doi: 10.1016/j.ncl.2016.05.001. Neurol Clin. 2016. PMID: 27445239 Review.
Aquatic training in MS: neurotherapeutic impact upon quality of life.
Frohman AN, Okuda DT, Beh S, Treadaway K, Mooi C, Davis SL, Shah A, Frohman TC, Frohman EM. Frohman AN, et al. Among authors: treadaway k. Ann Clin Transl Neurol. 2015 Aug;2(8):864-72. doi: 10.1002/acn3.220. Epub 2015 Jun 26. Ann Clin Transl Neurol. 2015. PMID: 26339680 Free PMC article.